Skip to main content

Table 4 FDA-approved combination regimens of immunotherapy and targeted therapies

From: Combination strategies to maximize the benefits of cancer immunotherapy

Cancer Line of therapy Targeted therapy Immunotherapy Clinical benefit Statistics Trial name and reference
Kidney cancer Metastatic, 1st line Axitinib Pembrolizumab 12-Mo OS: 89.9% versus 78.3% HR 0.53; 95% CI 0.38 to 0.74; P < 0.0001 KEYNOTE-426, [301]
Kidney cancer Metastatic, 1st line Cabozantinib Nivolumab PFS 16.6 versus 8.3 HR 0.51; 95% CI 0.41 to 0.64; P < 0.001 CheckMate -9ER, [303]
Kidney cancer Metastatic, 1st line Axitinib Avelumab PFS 13.8 versus 7.2 mos, HR 0.61; 95% CI, 0.47 to 0.79; P < 0.001 JAVELIN Renal 101, [302]
Endometrial cancer not MSI-H or dMMR Metastatic, salvage Lenvatinib Pembrolizumab ORR of 38.3% (95% CI, 29–49%) Single-arm trial KEYNOTE-146, [306]
Hepatocellular carcinoma Unresectable, 1st line Bevacizumab Atezolizumab 12-mo OS: 67.2% versus 54.6% for sorafenib HR 0.58; 95% CI 0.42 to 0.79; P < 0.001 IMbrave150, [309]
BRAF V600( +) advanced melanoma Advanced, 1st line Vemurafenib + cobimetinib Atezolizumab PFS 15.1 versus 10.6 mo HR 0·78; 95% CI 0·63–0·97; p = 0·025 IMspire150, [313]